ASTX295 + Olaparib: A Targeted Strategy for BRCA2‑Mutant, TP53‑Wild‑Type Cancers
ASTX295 is an experimental cancer drug that works by turning on a powerful tumor‑suppressor protein called p53 in cancer cells that still have a normal version of the gene TP53. In many cancers, p53 is not broken but is kept switched off by another protein called MDM2, which constantly tags p53 for destruction. ASTX295 blocks […]
